Personalised Approaches to Improving the Effect of Anti-platelet Agents: Where Do We Stand?
Guardado en:
Autores principales: | Lucas C Godoy, Michael E Farkouh |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/51db6b63c2a0408a9dc81374154e596b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Behavioural Interventions to Reduce Cardiovascular Risk: Where Do We Stand?
por: Gianluigi Savarese
Publicado: (2019) -
Sleep Apnoea and AF: Where Do We Stand? Practical Advice for Clinicians
por: Suneet Mittal, et al.
Publicado: (2021) -
Coronavirus Disease 2019: Where are we and Where are we Going? Intersections Between Coronavirus Disease 2019 and the Heart
por: Emilia D’Elia, et al.
Publicado: (2020) -
New Oral AntiCoagulant Use in REnal Disease and AF (NOACURE-AF) Where do we stand? An expert consensus view using the Delphi method
por: Ali Çoner
Publicado: (2021) -
New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) Where do we stand?: An expert consensus view using the Delphi method
por: Mustafa Arıcı, et al.
Publicado: (2021)